A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...
“While GLP-1-based therapies have revolutionized patient care for obesity ... harmful triglycerides and cholesterol while ...
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
Lixisenatide: A type of glucagon-like peptide-1 (GLP-1) receptor agonist to help lower blood sugar in people with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback